Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neele Heitmann

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Scientific Reports|August 1, 2024
Siponimod treatment response shows partial BDNF dependency in multiple sclerosis modelsHasan Hüseyin Hendek, Alina Blusch, Neele Heitmann, et al.
Frontiers in Immunology|May 1, 2025
The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigmRobert Hoffrogge, Anna Karachunskaya, Neele Heitmann, et al.
Therapeutic Advances in Neurological Disorders|December 15, 2022
Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccinationSimon Faissner, Neele Heitmann, Ricarda Rohling, et al.
Frontiers in Immunology|August 8, 2025
Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigmRobert Hoffrogge, Anna Karachunskaya, Neele Heitmann, et al.
Frontiers in Immunology|September 19, 2022
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccinationSimon Faissner, Neele Heitmann, Carlos Plaza-Sirvent, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Scientific Reports|August 1, 2024
Siponimod treatment response shows partial BDNF dependency in multiple sclerosis modelsHasan Hüseyin Hendek, Alina Blusch, Neele Heitmann, et al.
Frontiers in Immunology|May 1, 2025
The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigmRobert Hoffrogge, Anna Karachunskaya, Neele Heitmann, et al.
Therapeutic Advances in Neurological Disorders|December 15, 2022
Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccinationSimon Faissner, Neele Heitmann, Ricarda Rohling, et al.
Frontiers in Immunology|August 8, 2025
Correction: The P2X7R-antagonist AFC-5128 ameliorates chronic experimental autoimmune encephalomyelitis in a preventive and therapeutic paradigmRobert Hoffrogge, Anna Karachunskaya, Neele Heitmann, et al.
Frontiers in Immunology|September 19, 2022
Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccinationSimon Faissner, Neele Heitmann, Carlos Plaza-Sirvent, et al.
Pageof 1